BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society? Liver Int 2017;37:662-8. [PMID: 27804195 DOI: 10.1111/liv.13298] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2019;17:2093-2100.e3. [DOI: 10.1016/j.cgh.2019.01.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
2 Younossi ZM. The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review. Hepatology 2018;67:1160-2. [PMID: 29023922 DOI: 10.1002/hep.29580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, Mondelli MU. The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver Int. 2017;37:159-172. [PMID: 27748564 DOI: 10.1111/liv.13272] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
4 Li W, Chang TS, Chang SZ, Chen CH, Chen MY. Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach. BMC Infect Dis 2020;20:737. [PMID: 33028228 DOI: 10.1186/s12879-020-05435-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Younossi Z, Blissett D, Blissett R, Henry L, Younossi Y, Beckerman R, Hunt S. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. Liver Int 2018;38:258-65. [PMID: 28719013 DOI: 10.1111/liv.13519] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
6 Cipriano LE, Goldhaber-Fiebert JD. Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy Pract 2018;3:2381468318776634. [PMID: 30288448 DOI: 10.1177/2381468318776634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
7 Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. Hepatology. 2018;67:847-857. [PMID: 29108121 DOI: 10.1002/hep.29642] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
8 Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F. Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Liver Int 2019;39:1837-44. [PMID: 31173468 DOI: 10.1111/liv.14171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
9 Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018;25 Suppl 3:6-14. [PMID: 30398294 DOI: 10.1111/jvh.13005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
10 Younossi Z, Stepanova M, Omata M, Mizokami M, Walters M, Hunt S. Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. Health Qual Life Outcomes 2017;15:25. [PMID: 28143559 DOI: 10.1186/s12955-017-0598-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
11 Younossi ZM, Stepanova M, Henry L, Han KH, Ahn SH, Lim YS, Chuang WL, Kao JH, Kinh N, Lai CL, Yuen MF, Chan HL, Lai W. The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. Liver Int. 2018;38:1179-1187. [PMID: 29197140 DOI: 10.1111/liv.13650] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
12 Perazzo H, Jorge MJ, Silva JC, Avellar AM, Silva PS, Romero C, Veloso VG, Mujica-Mota R, Anderson R, Hyde C, Castro R. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil. BMC Gastroenterol 2017;17:119. [PMID: 29169329 DOI: 10.1186/s12876-017-0676-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. J Viral Hepat 2018;25:945-51. [DOI: 10.1111/jvh.12886] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
14 Puig-Junoy J, Pascual-Argente N, Puig-Codina L, Planellas L, Solozabal M. Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol 2018;12:1251-63. [PMID: 30791790 DOI: 10.1080/17474124.2018.1540929] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
15 Bush H, Rafiq N, Younossi ZM. Implementation of Value-based Medicine (VBM) to Patients With Chronic Hepatitis C (HCV) Infection. J Clin Gastroenterol 2019;53:262-8. [PMID: 30681638 DOI: 10.1097/MCG.0000000000001174] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]